A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer

NCT00116753 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

460

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Degarelix
DRUG: Degarelix
DRUG: Degarelix

Sponsor

Ferring Pharmaceuticals